121 related articles for article (PubMed ID: 16740539)
1. Agency criticises drug trial.
Day M
BMJ; 2006 Jun; 332(7553):1290. PubMed ID: 16740539
[No Abstract] [Full Text] [Related]
2. Inquiries in Britain uncover loopholes in drug trials.
Rosenthal E
N Y Times Web; 2006 Aug; ():A3. PubMed ID: 16909495
[No Abstract] [Full Text] [Related]
3. Does the TGN1412 trial disaster have lessons for clinical trials in India?
George T; Srinivasan S
Natl Med J India; 2006; 19(5):283-6. PubMed ID: 17203685
[No Abstract] [Full Text] [Related]
4. London's disastrous drug trial has serious side effects for research.
Wadman M
Nature; 2006 Mar; 440(7083):388-9. PubMed ID: 16554763
[No Abstract] [Full Text] [Related]
5. High stakes, high risks.
Lancet Oncol; 2007 Feb; 8(2):85. PubMed ID: 17267317
[No Abstract] [Full Text] [Related]
6. Further lessons from the TGN1412 tragedy.
Goodyear MD
BMJ; 2006 Aug; 333(7562):270-1. PubMed ID: 16888292
[No Abstract] [Full Text] [Related]
7. Learning from the TGN1412 trial.
Goodyear M
BMJ; 2006 Mar; 332(7543):677-8. PubMed ID: 16554332
[TBL] [Abstract][Full Text] [Related]
8. Severe adverse reactions prompt call for trial design changes.
Mayor S
BMJ; 2006 Mar; 332(7543):683. PubMed ID: 16565101
[No Abstract] [Full Text] [Related]
9. British rethinking test rules after drug trial nearly kills 6.
Rosenthal E
N Y Times Web; 2006 Apr; ():A1, A6. PubMed ID: 16642579
[No Abstract] [Full Text] [Related]
10. Volunteers at risk.
Drazen JM
N Engl J Med; 2006 Sep; 355(10):1060-1. PubMed ID: 16908488
[No Abstract] [Full Text] [Related]
11. TeGenero fiasco prompts regulatory rethink.
Sheridan C
Nat Biotechnol; 2006 May; 24(5):475-6. PubMed ID: 16680111
[No Abstract] [Full Text] [Related]
12. Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.
Muller PY
Adv Drug Deliv Rev; 2011 Jun; 63(7):511-7. PubMed ID: 21034787
[TBL] [Abstract][Full Text] [Related]
13. Drugs tests on trial.
Nature; 2006 Apr; 440(7087):970. PubMed ID: 16625159
[No Abstract] [Full Text] [Related]
14. [What happened on March 13th at the Northwick Park Hospital in London?].
Nau JY
Rev Med Suisse; 2006 Apr; 2(63):1133. PubMed ID: 16711457
[No Abstract] [Full Text] [Related]
15. [New catastrophe in pharmacological treatment--the crisis of clinical studies? Acute organ failure after administration of TGN1412].
Jerie P
Cas Lek Cesk; 2006; 145(6):426. PubMed ID: 16835991
[No Abstract] [Full Text] [Related]
16. Cytokine storm and an anti-CD28 monoclonal antibody.
Gardner K
N Engl J Med; 2006 Dec; 355(24):2591-2; author reply 2593-4. PubMed ID: 17171819
[No Abstract] [Full Text] [Related]
17. Phase 2 clinical trials started on PRO 140.
AIDS Patient Care STDS; 2008 Feb; 22(2):159-60. PubMed ID: 18273941
[No Abstract] [Full Text] [Related]
18. Immunostimulatory antibodies: challenging the drug testing paradigm.
Bhogal N; Combes R
Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
[TBL] [Abstract][Full Text] [Related]
19. Silence is not the best medicine: requiring disclosure of clinical trial data for abandoned drugs.
Powell B
J Leg Med; 2012 Oct; 33(4):571-92. PubMed ID: 23216153
[No Abstract] [Full Text] [Related]
20. Establishing risk of human experimentation with drugs: lessons from TGN1412.
Kenter MJ; Cohen AF
Lancet; 2006 Oct; 368(9544):1387-91. PubMed ID: 17046471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
